Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial conducted in the USA
Multiple endocrine neoplasia type 2 (MEN2) syndrome also represents an absolute contraindication
While these are different trials with different populations, the triple-agonist mechanism appears to produce faster and slightly greater weight loss
Im not constantly thinking about food, and the weight is finally coming off. Its important to note that these injections arent a magic bullet
Beyond BBQ, I sometimes switch it up with a sugar-free teriyaki, a zesty lemon-herb marinade, or even a homemade vinaigrette for a different flavor profile
But they have already made their mark in the field of diabetes and obesity